Type 2 Diabetes Mellitus Clinical Trial
— MESSAGESOfficial title:
Diabetes MESSAGES (Medical Care, Education, Social Support, And Goal-setting to Empower Self-management): Implementing Diabetes Group Visits and Text Messaging in Community Health Centers
Verified date | November 2022 |
Source | University of Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetes group visits, shared appointments where patients receive self-management education in a group setting and have a medical visit, are a promising way to deliver high quality diabetes care. Group visits can improve glycemic control and decrease healthcare utilization. To date, no studies have systematically implemented a diabetes group visit intervention in a network of U.S. community health centers. The University of Chicago is partnering with Midwest Clinicians' Network (MWCN), a member organization of 130 health centers across ten Midwestern states. Approximately half of all Federally Qualified Health Centers in this region are affiliated with MWCN. The objectives of the study are [1] providers and staff at 20 health centers will have the requisite knowledge, skills, and motivation to implement a diabetes group visit plus text messaging intervention at their sites; [2] changes in diabetes processes of care; knowledge, attitudes, and skills for diabetes self-management; clinical outcomes; and health care utilization for patients participating in the diabetes group visit program will be evaluated; and [3] the diabetes group visit program will be available for dissemination among and use by health centers and healthcare providers at the local, state, regional, and national levels.
Status | Completed |
Enrollment | 265 |
Est. completion date | June 30, 2022 |
Est. primary completion date | May 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older - diagnosis of type 2 diabetes - attended at least two appointments at the HC within the past year, with at least one of them being during the past six months - last documented A1c result greater than or equal to 8.0% (test must have been done during the last 6 months) - own a cellular phone with text messaging capabilities - have the ability to read and send text messages - English or Spanish speaking Exclusion Criteria: - pregnant or planning to become pregnant - uncontrolled psychiatric problem - dementia or other cognitive impairment - hearing difficulties or severe physical disability that would prevent them from participation in group visit - planning to relocate in the next year or leave the area during the group visit period |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Chicago | CareMessage, Midwest Clinicians' Network |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient engagement | Attendance/participation in group visits, text messaging, and booster sessions | through study completion, an average of 2 years | |
Other | Health center provider/staff preparedness | Capacity, confidence, motivation, perceived benefits and barriers | change from pre- to post-training (from baseline to 1 month, 7 month, and 16 month) | |
Other | Health center provider/staff satisfaction | Satisfaction with training, group visits, and text messaging | post-training (16 month) | |
Primary | Hemoglobin A1C | change from baseline to 12 months | ||
Secondary | Hemoglobin A1C | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | ||
Secondary | Blood pressure | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | ||
Secondary | Weight | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | ||
Secondary | Cholesterol | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | ||
Secondary | Diabetes processes of care | Receipt of recommended screenings, exams, referrals, and vaccinations | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | |
Secondary | Medication management of diabetes | changes in prescribed diabetes medications for patients with inadequate diabetes control | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | |
Secondary | Number of hypoglycemic events | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Number of hospital admissions | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | ||
Secondary | Number of primary care, specialist, and ER visits | baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only | ||
Secondary | Smoking status | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Health related quality of life (SF-12) | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Depression (PHQ-2) | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Summary of Diabetes Self-Care Activities Measure | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Understanding of Diabetes Self-Management (Diabetes Care Profile) | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Attitudes Towards Diabetes (Diabetes Care Profile) | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Diabetes Distress Scale (DDS-2) | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Diabetes Quality of Life Scale | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Diabetes Self-Empowerment Scale | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Diabetes Social Support Scale | baseline, 6 month, and 12 month for intervention patients only | ||
Secondary | Patient satisfaction with intervention | 6 month and 12 month for intervention patients only | ||
Secondary | CAHPS Overall Rating | Patient satisfaction with overall care at health center | baseline, 6 month, and 12 month for intervention patients only | |
Secondary | CAHPS Cultural Competency | Patient satisfaction with cultural competency of care at health center | baseline, 6 month, and 12 month for intervention patients only | |
Secondary | CAHPS Provider Communication | Patient satisfaction with provider communication at health center | baseline, 6 month, and 12 month for intervention patients only |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |